Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 03-2026 | 03-2025 | 03-2024 | 03-2023 | 03-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,485,474 | 208,000 | 165,000 | 995,000 | 1,286,000 |
| Depreciation Amortization | 1,284,320 | 1,328,000 | 1,045,000 | 795,000 | 653,000 |
| Accounts receivable | -421,040 | -698,000 | -371,000 | -36,000 | -66,000 |
| Accounts payable and accrued liabilities | -2,026 | -76,000 | 195,000 | -92,000 | -83,000 |
| Other Working Capital | -1,180,945 | -1,679,000 | -826,000 | -703,000 | -297,000 |
| Other Operating Activity | 1,531,459 | 2,214,000 | 934,000 | 1,505,000 | 617,000 |
| Operating Cash Flow | $3,697,241 | $1,297,000 | $1,142,000 | $2,464,000 | $2,110,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -380,972 | -247,000 | -179,000 | -274,000 | -248,000 |
| Net Acquisitions | N/A | N/A | -5,199,000 | N/A | -5,000 |
| Sale Of Investment | N/A | 86,000 | N/A | 95,000 | N/A |
| Purchase Sale Intangibles | -177,685 | -128,000 | -294,000 | -390,000 | -176,000 |
| Other Investing Activity | -59,393 | -435,000 | -223,000 | -456,000 | -259,000 |
| Investing Cash Flow | $-440,365 | $-596,000 | $-5,601,000 | $-635,000 | $-512,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -1,225,125 | -1,576,000 | 2,148,000 | N/A | N/A |
| Debt Issued | N/A | 1,333,000 | 3,128,000 | 263,000 | -246,000 |
| Debt Repayment | -539,834 | -347,000 | -168,000 | -376,000 | -246,000 |
| Common Stock Repurchased | -4,818 | -46,000 | -71,000 | -455,000 | -416,000 |
| Dividend Paid | -898,253 | -860,000 | -773,000 | -755,000 | -699,000 |
| Other Financing Activity | -3,512 | -246,000 | -197,000 | -148,000 | -166,000 |
| Financing Cash Flow | $-2,671,542 | $-1,742,000 | $4,067,000 | $-1,471,000 | $-1,773,000 |
| Exchange Rate Effect | 30,010 | 60,000 | 120,000 | 99,000 | 91,000 |
| Beginning Cash Position | 1,243,255 | 2,238,000 | 2,496,000 | 2,376,000 | 2,673,000 |
| End Cash Position | 1,858,593 | 1,256,000 | 2,223,000 | 2,833,000 | 2,590,000 |
| Net Cash Flow | $615,344 | $-982,000 | $-273,000 | $457,000 | $-83,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 3,697,241 | 1,297,000 | 1,142,000 | 2,464,000 | 2,110,000 |
| Capital Expenditure | -380,972 | -247,000 | -252,000 | -274,000 | -252,000 |
| Free Cash Flow | 3,316,269 | 1,050,000 | 890,000 | 2,190,000 | 1,858,000 |